Background-Continuous-flow left ventricular assist devices (LVAD) are increasingly used for patients with end-stage heart failure (HF). We analyzed the effects of ventricular decompression by continuous-flow versus pulsatile-flow LVADs on myocardial structure and function in this population. Methods and Results-Sixty-one patients who underwent LVAD implantation as bridge-to-transplant were analyzed (pulsatile-flow LVAD: group P, nϭ31; continuous-flow LVAD: group C, nϭ30 
C ardiac transplantation is the only curative treatment for patients with advanced heart failure, but its use is severely limited because of donor shortage. 1, 2 Over the last decades, the advent of left ventricular assist devices (LVADs) has provided a novel bridging intervention for patients awaiting heart transplantation. More recently, mechanical circulatory support has evolved into a standard therapy for patients with advanced heart failure, [3] [4] [5] not only as a bridge to cardiac transplantation but also as a destination therapy or a bridge to myocardial recovery. 6, 7 
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The first generation of implantable LVADs were pulsatile devices mimicking the physiological action of the human heart and with cardiac output defined by the pulsatility of the LVAD. These devices often required a median sternotomy and creation of a pump pocket, 8 which imposes a higher risk of perioperative morbidity and mortality. 9 In recent years, continuous-flow (nonpulsatile) devices have been used more widely because of their advantage of smaller size, longer durability, higher energy efficiency, less thrombogenicity, and less surgical trauma compared with pulsatile-flow LVADs. 10, 11 Several studies demonstrated that continuous-flow LVADs were similarly effective or even better in transplant rate and posttransplant outcome, 5 also showing fewer LVAD-related complications when compared with pulsatile-flow devices. 12 Furthermore, continuous-flow LVADs maintain adequate end-organ perfusion regardless of generating normal pulsatile hemodynamics. 13 However, the specific molecular differences in myocardial metabolism, inflammation, and ultrastructure of continuous-flow versus pulsatile-flow devices have not been fully elucidated. Of note, one recent study has reported that unloading of the left ventricle by continuous-flow LVADs deranged the physiological profile of myocardial energy utilization and vascular hemodynamics, whereas pulsatile unloading preserved more physiological values. 14 Advanced heart failure is characterized by increased extracellular matrix (ECM) turnover and fibrosis leading to attenuation of myocardial elasticity and increased stiffness, which results in diastolic myocardial dysfunction. 15 Previous studies reported that acute decompensation of patients with heart failure was associated with transient increases in markers of ECM turnover that may reflect an acceleration of pathological myocardial remodeling. 16, 17 The aim of this study was to investigate differences in echocardiographic parameters of systolic and diastolic function as well as myocardial and circulating markers of ECM turnover and cardiac fibrosis after implantation of continuous-flow versus pulsatile-flow LVADs.
Methods

Study Design
We retrospectively analyzed 61 patients (52 male, 9 female) with advanced heart failure undergoing LVAD implantation at Columbia University Medical Center between January 2002 and May 2010. The patients were divided into either group P, with pulsatile-flow LVAD, or group C, with continuous-flow LVAD. The LVAD setting in group C was adjusted to maintain an adequate cardiac output, accompanied by intermittent aortic valve opening as tolerated by the patients without increases in pulmonary arterial hypertension or a septal shift indicating right ventricular volume overload. Clinical and laboratory characteristics of all patients and hemodynamic conditions within 5 days before the LVAD implantation were compared between the groups. The duration of heart failure was defined as days from the patient's first diagnosis of heart failure to the day of LVAD surgery. Conventional echocardiograms accompanied by tissue Doppler parameters were obtained from all patients within 5 days before the LVAD surgery and at 1 month after the surgery. Laboratory examinations including plasma B-type natriuretic peptide (BNP) values within 5 days before the LVAD surgery and at various time points after the surgery were obtained. Serum samples of all patients as well as myocardial specimens in a subset of patients (nϭ21) were collected at the time of LVAD implantation and explantation.
The present study was approved by the Institutional Review Board of Columbia University Medical Center. All patients provided written informed consent before inclusion into the study.
Echocardiography
Both conventional echocardiography and tissue Doppler analysis were performed using the Sonos-5500 or Sonos-7500 machines (Philips Healthcare Corp, Andover, MA). A standard, comprehensive M-mode, 2D echocardiogram, and Doppler study were performed. The routine standard echocardiographic examination included measurements of thickness of the ventricular septum and LV posterior wall and end-systolic and end-diastolic LV diameters from M-mode or 2D imaging. The LV ejection fraction (LVEF) was calculated by biplane Simpson method from apical 4-and 2-chamber views. 18 Mitral inflow was obtained by pulsed-wave Doppler echocardiography with the sample volume between mitral leaflet tips during diastole, and peak early (E) and late (A) transmitral filling velocities and their ratio (E/A), and deceleration time of E were measured. The peak positive dP/dt (dP/ dt max , first derivative of LV pressure with respect to time) as an index of contractility was calculated based on continuous wave Doppler determination of the velocities in mitral regurgitant jets. 19 Early diastolic annular velocity (EЈ) was obtained by placing a tissue Doppler sample volume at the septal and lateral mitral annulus in the apical 4-chamber view, and the E/EЈ ratio was calculated. Quantitative assessment of right ventricular function by echocardiogram is technically difficult especially in patients with severe heart failure and on device support; therefore, we only used LV-related parameters in the present study. All measurements were performed from 5 cardiac cycles and then averaged.
Serum Analysis
For analysis of plasma ECM levels, peripheral venous blood samples were collected and stored after centrifugation at Ϫ70°C until the assays were performed. The plasma levels of matrix metalloproteinases (MMP)-2 and MMP-9, tissue inhibitors of MMPs (TIMP-1 and MMP-4), and osteopontin (OPN), were measured with commercially available enzyme-linked immunosorbent assay kits (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom, for MMPs and TIMP-1 and TIMP-2; R&D Systems, Minneapolis, MN, for TIMP-4 and OPN). Circulating levels of BNP were analyzed by the institutional core laboratory.
Gene Expression Analysis
In a subset of 18 patients including 7 patients in group P and 11 patients in group C, myocardial specimens were collected at the time of LVAD implantation and at the time of LVAD explantation during heart transplantation. Total RNA was extracted from myocardial tissue, and the abundance of specific mRNAs was determined by reverse transcription and real-time polymerase chain reaction analysis with a Prism 7700 Sequence Detector (Perkin-Elmer, Foster City, CA). Sequences of primers and TaqMan probes specific for BNP, MMP-2 or MMP-9, TIMP-1 or TIMP-2, and OPN were described previously. 20 -22 Gene expression was normalized using expression of 18S mRNA and expressed as relative expression.
Histology
In a subset of 18 patients that included 10 patients from group P and 8 patients from group C, sections of myocardial tissue obtained at the time of LVAD implantation and at the time of explantation were prepared after paraffin fixation and stained with hematoxylin and eosin and Masson trichrome. Myocardial fibrosis was quantified on serial sections using Masson trichrome staining for the detection of collagen. Areas of fibrosis were analyzed using the ImagePro software (NIH) and expressed as percent of total section area. Myocyte cross-sectional area (CSA) was analyzed after semiquantitative analysis with circumferential markings of the myocytes using ImagePro software and expression of average cross-sectional area and distribution of fiber sizes within each sample.
Statistical Analysis
Data are presented as meanϮSD. Normality was evaluated for each variable from normal distribution plots and histograms and by the Kolmogorov-Smirnov test. The echocardiographic and laboratory variables, as well as serum and myocardial expression of ECM markers and BNP before and after surgery were compared between the groups with the Student unpaired 2-tailed t test. The values before and after the surgery in each group of patients were assessed with the Student paired t test. A probability value of Ͻ0.05 was considered statistically significant. All data were analyzed using the Statistical Analysis Systems software JMP 7.0 (SAS Institute Inc, Cary, NC).
Results
Baseline Characteristics
We analyzed 61 patients undergoing placement of a LVAD at our institution. A total of 31 patients underwent implantation of a pulsatile-flow LVAD (group P; 29 patients with HeartMate XVE and 2 patients with Thoratec PVAD, both from Thoratec Corp, Pleasanton, CA). The other 30 patients underwent implantation of a continuous-flow LVAD (group C; 27 patients with HeartMate II, Thoratec Corp, 2 patients with Durahart, Teramo Heart Inc, and 1 patient with DeBakey VAD, MicroMed Cardiovascular Inc).
Clinical characteristics of all patients are summarized in Table 1 . The duration of heart failure ranged from 0 to 2792 days (median, 237 days) for group P and 4 to 3632 days (median, 170 days) for group C. The duration of LVAD support ranged from 31 day to 662 days (median, 123 days) for group P and 48 days to 531 days (median, 100 days) for group C (PϭNS). Clinical characteristics and medical treatment were not significantly different between the main cohort and the subgroup of patients available for myocardial gene expression or histological analysis (Table 1 and online-only  Data Supplement Tables 1 to 3 ).
Laboratory Examinations
The comparison of laboratory examinations before and after the surgery in each group is summarized in Table 2 . Platelet count and sodium concentration increased, and blood urea nitrogen, total bilirubin and direct bilirubin concentration decreased after LVAD implantation in both groups. There was no significant difference between preoperative and postoperative laboratory values between group P and group C.
Echocardiographic Data
A comparison of echocardiographic parameters before and after the surgery in each group is listed in Table 3 . LV end-diastolic dimension (LVEDD) and left ventricular endsystolic dimension (LVESD) decreased after LVAD implantation in both groups. The interventricular septal wall thickness became thicker only in group P. LVEF ( Figure 1A ) and percent fractional shortening increased only in group P but not in group C. The dP/dt max increased in both groups ( Figure  1B ). The mitral annular velocity of EЈ increased with LVAD support in both groups; however, the E/EЈ ratio decreased only in group P ( Figure 1C ).
The intergroup comparison of preoperative echocardiographic parameters revealed no significant differences. In contrast, postoperative LVEDD and LVESD were smaller, and LVEF ( Figure  1A ), percent fractional shortening, and dP/dt max ( Figure 1B ) were greater in group P than in group C (Pϭ0.028, PϽ0.0001, PϽ0.0001, Pϭ0.004, respectively). Postoperative mitral E flow and annular velocity of EЈ were greater, and the E/EЈ ratio ( Figure 1C ) was lower in group P than in group C (Pϭ0.036, PϽ0.0001, Pϭ0.0002, respectively).
Serum Levels of ECM Biomarkers and BNP
To characterize the impact of the different devices on myocardial structure and strain, we analyzed circulating levels of BNP and ECM markers (Figure 2 ). Serum BNP levels decreased in both groups after LVAD implantation (1486.9Ϯ1196.2 to 552.6Ϯ340.6 for group P, PϽ0.0001; 1500.4Ϯ1486.9 to 965.4Ϯ805.7 for group C, PϽ0.0001, Figure 2A) . The preoperative BNP level was not different between the groups; however, postoperative BNP levels was lower in group P compared with group C (552.6Ϯ340.6 versus 965.4Ϯ805.7 pg/mL, Pϭ0.007, Figure 2A) . Serum MMP9 and TIMP4 levels after LVAD implantation were lower than the values before the surgery only in group P (309.0Ϯ220.2 versus 740.9Ϯ459.0 ng/mL, Pϭ0.003, Figure  2C ; 1490.9Ϯ622.4 versus 2491.5Ϯ753.4, Pϭ0.033, Figure 2E) ; however, none of the serum ECM markers were significantly reduced after the surgery in group C. There was no significant difference of preoperative serum ECM markers between group P and group C. Serum MMP-9 ( Figure 2C ) and TIMP-4 ( Figure 2E ) levels after LVAD implant were lower in group P compared with group C (309.0Ϯ220.2 versus 475.2Ϯ336.9 ng/mL, Pϭ0.013; 1490.9Ϯ622.4 versus 2014.3Ϯ452.4 pg/mL, Pϭ0.0002, respectively). No significant differences in circulating BNP and ECM markers were found between patients with ischemic versus nonischemic etiology.
Myocardial Gene Expression of ECM Biomarkers and BNP
The myocardial expression levels of BNP at the time of LVAD explantation were lower than at LVAD implantation in both groups (0.2Ϯ0.1 versus 1.1Ϯ1.1 AU, Pϭ0.024 for group P; 0.3Ϯ0.2 versus 1.0Ϯ1.1 AU, Pϭ0.049 for group C, Figure 3A) . The myocardial gene expressions of MMP2 and 9 ( Figure 3B, 3C) and No significant difference was found in changes of gene expression of SERCA2a, phospholamban, calsequestrin, and the ryanodine receptor 2 in patients with pulsatile versus patients with nonpulsatile devices. There is a uniform increase in these key genes of calcium homeostasis without significant differences between the two types of devices (data not shown).
Histology
The area of fibrosis in myocardial samples was reduced after LVAD implantation compared with the values before LVAD placement in both groups (31.7Ϯ2.7% to 22.7Ϯ5.9%, Pϭ0.016 for group P, 34.4Ϯ3.6% to 27.6Ϯ3.2%, Pϭ0.016 for group C; Figure 4A ). The CSA was also reduced postoperatively in both groups (221.5Ϯ9. for group C; Figure 4B ). The changes were not statistically different between the groups.
Discussion
In the current study, we demonstrate distinct differences in myocardial function and structure of patients with pulsatile versus continuous-flow LVADs. LV systolic and diastolic function assessed by serial echocardiography was significantly better in patients with pulsatile devices compared with patients with continuous-flow devices. This was reflected by a greater decrease of circulating levels of BNP, TIMP-4, and MMP-9 in patients with pulsatile-flow devices compared with those with continuous-flow devices, although myocardial gene expression of BNP and markers of ECM turnover except for TIMP-4 showed similar decreases in both types of devices. Myocardial expression levels of TIMP-4 decreased only in patients with pulsatile devices. Mechanical unloading with both pulsatile and continuous flow patterns also reduced myocardial fibrosis and myocyte fiber CSA in similar degrees. The use of continuous-flow LVADs has been increasing over the last years. The advantages of continuous-flow over pulsatileflow devices are their smaller size reducing surgical trauma, applicability for smaller patients, higher mechanical reliability, better energy efficiency, limited blood-containing surfaces, and reduced thrombogenicity. 10, 11 Continuous-flow devices have also reduced the rate of device-related infection to nearly half of that with pulsatile-flow devices. 5 From a hemodynamic perspective, continuous-flow devices unload the LV constantly throughout the cardiac cycle, whereas pulsatile devices unload the ventricle only during a selected portion of the cardiac cycle. Therefore, continuous-flow devices do not generate normal pulsatile hemodynamics. Concerns still exist regarding the effects of chronic, non-pulsatile blood flow on cardiovascular architecture, end-organ perfusion, and long-term patient outcomes in this "pulseless" patient population. Continuous-flow devices have been shown to change the physiological myocardial contractile profile, whereas pulsatile device preserves more physiological values, 14 although this observation was limited to acute animal models. Of note, Radovancevic et al 23 reported that both continuous-flow and pulsatile-flow devices provide adequate blood flow to maintain end-organ function; however, their study did not assess the specific effects of pulsatile versus nonpulsatile devices on native myocardial function. As far as we are aware, our present study is the first to apply a combination of serial echocardiograms, serum and myocardial ECM markers, and serial histological assessments to evaluate differences of continuous-flow versus pulsatile-flow devices on structure and function of the failing myocardium.
Reverse myocardial remodeling and functional recovery have been reported in some patients after device implantation, most often in patients who received pulsatile devices for acute myocardial failure. 7, 24, 25 A prospective study by Maybaum et al 24 showed regression of myocardial hypertrophy accompanied with functional recovery of the failing heart after device implantation even in patients with chronic heart failure. Mechanical unloading by continuous-flow devices impairs the contractile variation in endsystolic and end-diastolic LV volume and pressures to a greater extent than using pulsatile-flow devices. In our study, implantation of both device types resulted in reduced work load of the heart indicated by regression of myocyte hypertrophy and reduced CSA of myocardial fibers. Although it is not clear how a variation in ventricular volume and pressure affects myocardial reverse remodeling, it is commonly accepted that normal ventricular geometry depends on a consistent physiological pressure-volume relationship. Bartoli et al 14 demonstrated that pulsatile unloading normalizes the pressure-volume relationship of the failing myocardium by decreasing volume without affecting pressures.
Specific intrinsic characteristics of mechanical unloading are related to the type of LVADs, and it is known that pulsatile-flow devices more adequately decompress the LV. Continuous-flow devices currently available are considered active suction devices, and current treatment algorithms are designed to avoid inappropriate unloading, which may induce right ventricular dysfunction and failure. The LV is usually left as slightly distended in patients with continuous-flow devices, also to avoid suction events. Therefore, the degree of ventricular decompression is higher in pulsatile versus nonpulsatile devices, which explains the observed echocardiographic patterns but might also relate to the differences in biological effects documented in the current study. The more pronounced decrease in intraventricular filling pressure in patients with pulsatile devices is supported by a higher decrease in myocardial and circulating BNP.
Doppler echocardiography has become an invaluable tool for noninvasively determining LV diastolic pressure. 26 Elastic recoil, which is determined by ventricular end-systolic volume, is an important determinant of relaxation rate 27 which can influence ventricular stiffness. We performed serial echocardiograph- ic assessments both before and after implantation of a VAD in all patients of our cohort. Measurements of 5 cardiac cycles were averaged according to protocol proposed by Estep et al. 28 This is necessary to reduce variability in ventricular diameter caused by asynchrony between device filling and ejection of the native heart in patients with pulsatile devices. Further, we aimed to reduce variability caused by occasional opening of the aortic valve in patients with continuous-flow devices. Also, the images were obtained in the absence of respiratory variation during stopped respiration to avoid the influence of preload changes in blood volume load on the measurements. By using these techniques to obtain sufficient images from LVAD patients, we believe that our echocardiographic data strongly suggest that the magnitude of LV unloading was greater in pulsatile-flow devices than that in continuous-flow devices.
Mechanical unloading of the failing heart is associated with changes in myocardial structure and molecular markers of stretch, inflammation, fibrosis, and metabolism. Previous studies reported that patients with acute decompensated heart failure show an increase in markers of ECM turnover, 16, 17 which may be associated with myocardial remodeling. Circulating OPN may represent a marker of ventricular dilation and an indicator of the response to heart failure therapies promoting LV reverse remodeling. 22, 29 The cardiac OPN expression has been reported as a biomarker indicating ongoing cardiac inflammation preceding fibrosis and myocardial remodeling. 30 The discordance of serum levels and myocardial expression of certain markers might be caused by the fact that transcriptional changes within the myocardium and circulating protein levels may differ as the result of posttranslational regulation and modification. Previous reports indicated that LVAD support did not lead to complete restoration of micro RNA expression of the failing heart. 31 Another reason for this discordance could be the that the degree of LV unloading induced by continuous-flow devices was sufficient to alter BNP and matrix-regulating transcripts in the LV myocardium but did not sufficiently correct other sources of circulating BNP and matrix-regulating proteins. Further, sample collection is restricted to certain areas of the myocardium (apex for the implant, due to localization of the inflow cannula). There exists the possibility that other sites of the heart such as the atria, the right ventricle, or the vasculature are contributing to systemic protein changes. Further studies are required to investigate the difference in myocardial gene expression between both devices as well as to elucidate the specific relationship between myocardial gene expression levels and circulating levels of markers of ECM turnover and fibrosis in a larger cohort.
Our study has several limitations. First, the analysis is limited by its retrospective and observational nature comparing 2 procedures performed over different time periods. The majority of patients undergoing pulsatile-flow device implantation had surgery during an earlier period compared with those with continuous-flow devices, due to the recent decrease in implantation rates of pulsatile VADs. Nevertheless, the pre-and post-LVAD medical treatments were not significantly different between the groups (Table 1) , irrespective of the recent paradigm shifts in heart failure treatment including ␤-blocker and/or renin-angiotensin-aldosterone system inhibitor administration. We, therefore, believe that the era of LVAD surgery did not affect the results of our study. Prospective, randomized investigation would be theoretically ideal to validate our study; however, it is ethically impossible because of several advantage of continuous flow device over pulsatile flow device. 10, 11 Second, the studied patients were not consecutively selected. We evaluated only patients whose blood samples were collected at the time of LVAD implantation and explantation. Only a subset of those patients had also myocardial samples collected. Third, because of a limited set of data available, we could not demonstrate differences in the pulsatility index or device speed of continuousflow devices and its potential relation to myocardial biomarkers. We reviewed the relation between LVAD setting and LVEDD in patients with continuous-flow devices after the patients were sufficiently stabilized as outpatients. No correlation was found between LVAD settings and LVEDD during the chronic phase after device implantation. Finally, the histological analysis is restricted to certain areas of the myocardium due to the location of the inflow cannula in the implantation sample. Histological investigation of the right ventricle, which remained to be pulsatile under continues-flow LV support, was not performed.
Altogether, our study is the first systematic assessment of echocardiographic parameters of LV systolic and diastolic function of pulsatile versus nonpulsatile VADs in relation to molecular markers of myocardial reverse remodeling and ECM turnover. These observations can be implicated that a more profound unloading of the failing myocardium by pulsatile flow devices associated with a different profile of local and circulating myocardial biomarkers. These findings may have important clinical implications in particular for the concept of "bridge to recovery" and support the careful assessment and discussions of device type selection for individual patients with advanced heart failure. Although mechanical unloading with pulsatile-flow devices resulted in a higher degree of unloading, this is at least partially related to the specific usage pattern of continuous-flow devices at our center. It is conceivable that different continuous device speed settings could potentially produce equivalent myocardial unloading with subsequent structural and molecular reverse remodeling. Therefore, additional prospective studies are warranted to determine the association between continuous-flow device settings and myocardial recovery.
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CLINICAL PERSPECTIVE
Continuous-flow left ventricular assist devices (LVAD) are increasingly used for patients with end-stage heart failure. Continuous-flow devices have the advantage of smaller size, longer durability, higher energy efficiency, less thrombogenicity, and less surgical trauma compared with the previously used pulsatile-flow LVADs. We investigated the effects of ventricular unloading using continuous-flow versus pulsatile-flow LVADs on myocardial structure and function. We analyzed 31 patients with a pulsatile-flow LVAD and 30 patients with a continuous-flow LVAD. Echocardiographic parameters of systolic and diastolic function improved more in patients with pulsatile-flow LVAD compared with those with continuous-flow LVAD. Myocardial gene expression of extracellular matrix markers and brain natriuretic peptide as well as serum levels of brain natriuretic peptide, metalloproteinase-9, and tissue inhibitor of metalloproteinase-4 were more significantly reduced in patients with pulsatile-flow LVAD than those with continuous-flow LVAD. Our study is the first systematic assessment comparing pulsatile and nonpulsatile VADs in relation to these markers of myocardial reverse remodeling and extracellular matrix turnover. These observations demonstrate a more profound unloading of the failing myocardium by pulsatile-flow devices than by the continuous-flow devices currently used. These differences may be important if assist devices are implanted with the hope of supporting cardiac recovery.
